- Home
- GRVY vs MYGN Comparison
GRVY vs MYGN Comparison
Compare GRVY & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRVY
- MYGN
- Stock Information
- Founded
- GRVY 2000
- MYGN 1991
- Country
- GRVY South Korea
- MYGN United States
- Employees
- GRVY N/A
- MYGN N/A
- Industry
- GRVY Business Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GRVY Consumer Discretionary
- MYGN Health Care
- Exchange
- GRVY Nasdaq
- MYGN Nasdaq
- Market Cap
- GRVY 442.6M
- MYGN 423.1M
- IPO Year
- GRVY 2005
- MYGN 1995
- Fundamental
- Price
- GRVY $65.04
- MYGN $6.02
- Analyst Decision
- GRVY
- MYGN Hold
- Analyst Count
- GRVY 0
- MYGN 13
- Target Price
- GRVY N/A
- MYGN $13.50
- AVG Volume (30 Days)
- GRVY 14.6K
- MYGN 2.4M
- Earning Date
- GRVY 08-08-2025
- MYGN 08-05-2025
- Dividend Yield
- GRVY N/A
- MYGN N/A
- EPS Growth
- GRVY N/A
- MYGN N/A
- EPS
- GRVY 8.59
- MYGN N/A
- Revenue
- GRVY $404,804,469.00
- MYGN $832,900,000.00
- Revenue This Year
- GRVY N/A
- MYGN N/A
- Revenue Next Year
- GRVY N/A
- MYGN $6.64
- P/E Ratio
- GRVY $7.44
- MYGN N/A
- Revenue Growth
- GRVY N/A
- MYGN 3.83
- 52 Week Low
- GRVY $53.12
- MYGN $3.76
- 52 Week High
- GRVY $70.00
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- GRVY 52.64
- MYGN 62.34
- Support Level
- GRVY $62.56
- MYGN $5.23
- Resistance Level
- GRVY $70.00
- MYGN $6.07
- Average True Range (ATR)
- GRVY 2.27
- MYGN 0.39
- MACD
- GRVY -0.06
- MYGN 0.05
- Stochastic Oscillator
- GRVY 44.89
- MYGN 81.27
About GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.